Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CHTR1D
The experimentally established mechanism targets of Ergotamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.93 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 0.93 |
| ▸ | ADRA2C known ✓ | P18825 | 5/20 | 0.93 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.93 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.93 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.93 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.93 |
| ▸ | DRD2 | P14416 | 6/20 | 0.93 |
| ▸ | HTR2A | P28223 | 6/20 | 0.93 |
| ▸ | HTR2C | P28335 | 6/20 | 0.93 |
| ▸ | HTR6 | P50406 | 6/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.93 |
| ▸ | DRD3 | P35462 | 5/20 | 0.93 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.93 |
| ▸ | DRD1 | P21728 | 4/20 | 0.93 |
| ▸ | HTR2B | P41595 | 4/20 | 0.93 |
| ▸ | HTR1A | P08908 | 4/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.93 |
| ▸ | HTR1B | P28222 | 3/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ergotamine SCHEMBL134885 | 1.00 | CYP3A4 (0.93) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL8046 | 1.00 | CYP3A4 (0.93) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL8045 | 1.00 | CYP3A4 (0.93) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL29420131 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL22171508 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL29567350 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL783017 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL783018 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL1483 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL18134607 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12447144-B2 | 5HT agonists for treating disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4304554-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | Aquestive Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230346750-A1 | 5HT AGONISTS FOR TREATING DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-02 | — | — | US | disclosed |
| US-11648237-B2 | 5HT agonists for treating disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4152931-A1 | USE OF 4-PHENYLBUTYRIC ACID AND/OR 3-PHENYLBUTYRIC ACID AND/OR 2-PHENYLBUTYRIC ACID IN PREVENTING AND TREATING CRYPTOGAMIC DISEASES | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (FR) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022192476-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-4043016-A1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | The Regents of the University of California (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220226508-A1 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-21 | — | — | US | disclosed |
| EP-3976187-A1 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | The Regents of the University of California (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3261640-B1 | 5HT AGONISTS FOR TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114007692-A | Methods and compositions for treating epilepsy | 加利福尼亚大学董事会 | 2022-02-01 | — | — | CN | disclosed |
| EP-3943501-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | Halozyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226508-A1 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | HTR2B, HTR3B, HTR1B | ADRA2A 75/4885ADRA2B 30/4885ADRA2C 101/4885 |
| US-20230346750-A1 | 5HT AGONISTS FOR TREATING DISORDERS | HTR1A, HTR5A, HTR2A | ADRA2A 37/4885ADRA2B 103/4885ADRA2C 68/4885 |
| US-11648237-B2 | 5HT agonists for treating disorders | HTR1A, HTR5A, HTR2A | ADRA2A 37/4885ADRA2B 103/4885ADRA2C 68/4885 |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | SLC6A4, SLC6A2, TPH2 | ADRA2A 144/4885ADRA2B 113/4885ADRA2C 106/4885 |
| US-12447144-B2 | 5HT agonists for treating disorders | HTR1A, HTR5A, HTR2A | ADRA2A 37/4885ADRA2B 103/4885ADRA2C 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.